Tempest Therapeutics, Inc. Stock Issued During Period, Value, Conversion of Convertible Securities
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2022-12-31 was $0.00.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2022-09-30 was $0.00.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2022-06-30 was $0.00.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for the quarter ending 2022-03-31 was $30.00M.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2022 was $30.00M, a 0.00% change from fiscal 2021.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2021 was $30.00M, a 38361.54% increase from fiscal 2020.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2020 was $78.00K, a 29.73% decline from fiscal 2019.
- Tempest Therapeutics, Inc. stock issued during period, value, conversion of convertible securities for fiscal 2019 was $111.00K, a 99.92% decline from fiscal 2018.
| Period end | Stock Issued During Period, Value, Conversion of Convertible Securities 3 month | Stock Issued During Period, Value, Conversion of Convertible Securities 12 month |
|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $30.00M 10-K · filed 2023-03-22 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $30.00M derived: sum of 4 quarters · filed 2022-11-08 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $30.00M derived: sum of 4 quarters · filed 2022-08-15 |
| 2022-03-31 | $30.00M 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $30.00M 10-K · filed 2022-03-29 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $78.00K 10-K · filed 2021-03-29 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $78.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-06-30 | $0.00 10-Q · filed 2020-08-10 | $141.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2020-03-31 | $78.00K 10-Q · filed 2021-05-13 | $189.00K derived: sum of 4 quarters · filed 2021-05-13 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $111.00K 10-K · filed 2021-03-29 |
| 2019-09-30 | $63.00K 10-Q · filed 2020-11-09 | |
| 2019-06-30 | $48.00K 10-Q · filed 2020-08-10 | |
| 2018-12-31 | $132.92M 10-K · filed 2020-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B |